Array Biopharma (ARRY) Tops Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
Revenue Growth %: -16.4%
Financial Fact:
General and administrative: 7.86M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -16.4%
Financial Fact:
General and administrative: 7.86M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $28.61 million.
Cash, Cash Equivalents and Marketable Securities as of June 30, 2017 were $235.1 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- UBS Downgrades Array Technologies (ARRY) to Neutral
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
